Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide and Carboplatin in Recurrent Glioblastoma Multiforme
NCT00021307Phase 2Withdrawn
- Sponsor
- Fox Chase Cancer Center
- Primary completion
- Apr 2002
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 2, open-label, single-arm trial of temozolomide and carboplatin in glioblastoma multiforme (GBM), sponsored by Fox Chase Cancer Center. Primary endpoints: Maximum Tolerated Dose up to 24 weeks and Adverse Events up to 48 weeks. Status: withdrawn.
02
Drugs
temozolomidecarboplatin
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00021307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00021307.